Roche shells out $200M for rights to Vac­ci­body's neoanti­gen can­cer vac­cine

Roche’s Genen­tech arm is putting down $200 mil­lion in up­fronts and near-term pay­ments — and po­ten­tial­ly $515M more down the road — for glob­al rights to Nor­we­gian biotech Vac­ci­body’s neoanti­gen can­cer vac­cine can­di­date.

The com­pa­nies are join­ing forces to de­vel­op Vac­ci­body’s per­son­al­ized vac­cine can­di­date VB10.NEO in the US and Eu­rope. Ac­cord­ing to the li­cens­ing agree­ment, Vac­ci­body will see the can­di­date through Phase Ib de­vel­op­ment, af­ter which the big guns at Genen­tech will take over clin­i­cal de­vel­op­ment, man­u­fac­tur­ing and com­mer­cial­iza­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER